The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
|
---|---|
Published in |
Frontiers in oncology, August 2019
|
DOI | 10.3389/fonc.2019.00766 |
Pubmed ID | |
Authors |
Alessandro Ottaiano, Monica Capozzi, Salvatore Tafuto, Alfonso De Stefano, Chiara De Divitiis, Carmela Romano, Antonio Avallone, Guglielmo Nasti |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 17 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 4 | 24% |
Student > Master | 3 | 18% |
Researcher | 2 | 12% |
Student > Doctoral Student | 2 | 12% |
Student > Ph. D. Student | 2 | 12% |
Other | 2 | 12% |
Unknown | 2 | 12% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 4 | 24% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 18% |
Biochemistry, Genetics and Molecular Biology | 2 | 12% |
Unspecified | 1 | 6% |
Nursing and Health Professions | 1 | 6% |
Other | 3 | 18% |
Unknown | 3 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2022.
All research outputs
#15,179,141
of 25,385,509 outputs
Outputs from Frontiers in oncology
#4,554
of 22,432 outputs
Outputs of similar age
#183,518
of 353,823 outputs
Outputs of similar age from Frontiers in oncology
#106
of 332 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,432 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,823 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 332 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.